AmCad BioMed Corporation (AmCad) was founded in 2008 and was listed on Taipei Exchange in the March of 2015. AmCad BioMed Corporation is dedicated to developing innovative ultrasound Computer-Assisted Detection and Diagnosis (CAD) devices. AmCad's strong first-in-the-world pipeline includes AmCAD-UT: The World’s First Ultrasound CAD for Thyroid Cancers (FDA, CE Mark and TFDA) iSONO Aid: Revolutionizing Ultrasound Imaging. AmCAD-UO: Sleep Apnea Detection in 10 minutes. AmCAD-CA: Digital Cytology Analysis System. AmCAD-UV: Doppler Ultrasound Pulsatile Signal Analysis and Visualization Platform (FDA, CE Mark). AmCAD-US: Real Time Ultrasound Tissue Structure Analysis and Visualization Platform (FDA, CE Mark). The state-of-the-art pipeline aims for early detection and diagnosis of various types of cancers, such as thyroid cancers, breast cancers, etc., and diseases, including liver fibrosis and obstructive sleep apnea. AmCad's Blue Ocean Strategy for the CAD systems is to develop its own core-technology platforms by providing high value-added, state-of-the-art medical solutions targeting a wide variety of clinical applications and raising the global competition to a higher level.